Enstilar (Calcipotriene/Betamethasone) Patent Expiration, LOE Window & CMS Spending
Enstilar (Calcipotriene/Betamethasone) by Leo As: FDA Orange Book LOE 2031-12-10, 3 AB generics, $9.6M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Leo As |
| FDA Application & Pathway | N207589 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2031-12-10 |
| Orange Book Patents (*PED Extensions) | 10 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $9.6M |
| 2024 Medicare Part D Spend | $6.9M |
| 2024 Medicaid Spend | $2.7M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |